Time-based reperfusion in haemodynamically unstable pulmonary embolism patients: does early reperfusion therapy improve survival?

Eur Heart J Acute Cardiovasc Care. 2023 Oct 25;12(10):714-720. doi: 10.1093/ehjacc/zuad080.

Abstract

High-risk pulmonary embolism (PE) is associated with significant morbidity and mortality. Systemic thrombolysis remains the most evidenced-based treatment for haemodynamically unstable PE, but in daily clinical practice, it remains largely underused. In addition, unlike acute myocardial infarction or stroke, a clear time window for reperfusion therapy, including fibrinolysis, for high-risk PE has not been defined either for fibrinolysis or for the more recently incorporated options of catheter-based thrombolysis or thrombectomy. The aim of the present article is to review the current evidence supporting the potential benefit of earlier administration of reperfusion in haemodynamically unstable PE patients and suggest some potential strategies to further explore this issue.

Keywords: High risk; Mortality; Pulmonary embolism; Thrombolysis.

MeSH terms

  • Acute Disease
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Pulmonary Embolism* / therapy
  • Reperfusion
  • Thrombectomy
  • Thrombolytic Therapy*
  • Treatment Outcome

Substances

  • Fibrinolytic Agents